• A Company Dedicated to Safe Therapeutic Modulation of Monoamine Neurotransmitter

    Read more

  • Annual Report 2025

    April 28, 2026

    Read the report

  • Interim Report January – March 2026

    May 8, 2026

    Read the report

Press releases

Older releases

Latest reports

All reports

Calendar

All events

Share

Read more

Initiator Pharma Numbers

  • Expected Number of men affected by Erectile Dysfunction worldwide by 2025 322 million
  • Number of women in the US and Europe suffering from Vulvodynia 27 million
  • Men with Erectile Dysfunction who do not respond to drug therapy 40 %
Initiatorpharma-module-homepage-1-22102021

Initiator Pharma currently has a portfolio of five projects, of which three are in clinical development and two are in preclinical development.

View our Pipeline

CEO letter

“The first months of 2026 have been productive on several fronts and very important for Initiator Pharma. Patient enrolment in our Phase IIa proof-of-concept study in vulvodynia is advancing well. We have made a strategic decision to fully concentrate our resources on our most promising asset, pudafensine, and we have further strengthened our intellectual property position in Female Sexual Dysfunction.”

Read the full letter
Initiatorpharma-module-homepage-2-22102021

Monoamine transporters is a unique class of proteins that are located just outside the synaptic cleft (peri-synaptically), transporting monoamine transmitter overflow from the synaptic cleft back to the cytoplasm of the pre-synaptic neuron. Our unique monoamine reupdate inhibitors are targeting the monoamine transporters to increase the levels of monoamine transmitters in diseases.

Read more about our technology